脾脏CD169+Tim4+边缘嗜金属巨噬细胞对心肌梗死后伤口愈合至关重要
该研究在小鼠心肌梗死模型中证实,脾脏CD169+Tim4+边缘嗜金属巨噬细胞(MMMs)以Ly6Clow单核细胞形式循环并迁移至心脏,分化为CD169+Tim4+LYVE1low巨噬细胞,对清除凋亡中性粒细胞、抑制炎症和诱导修复表型不可或缺;在人类ST段抬高型心肌梗死患者中亦观察到循环CD169+Tim4+细胞扩增。
要点
- 脾脏MMMs经血液迁移至梗死心脏,分化为修复性巨噬细胞。
- MMMs对凋亡中性粒细胞清除、炎症抑制和修复表型诱导是必需的。
- LXR-α激动剂扩增脾脏MMMs可改善急性和长期心脏重构。
核心结论
- 脾脏CD169+Tim4+MMMs是心肌梗死后促消退和修复反应所必需的,可被调控以限制长期心力衰竭。
研究设计与样本
- 研究采用多种小鼠体内模型(手术MI、流式细胞术、单细胞RNA测序、谱系追踪、脾切除术、联体共生、过继转移等)及人类ST段抬高型MI患者与稳定冠心病对照的循环CD169+Tim4+单核细胞流式检测。
主要发现
- 脾脏CD169+Tim4+MMMs以表达巨噬细胞标志物的Ly6Clow单核细胞形式在血液中循环,并帮助 naive 心脏中CD169+Tim4+CCR2-LYVE1low巨噬细胞的填充。
- 急性MI后,脾脏MMMs增强吞噬作用及CCR3和CCR4表达,大量动员至心脏,导致具有免疫调节和促消退基因特征的CD169+Tim4+LYVE1low心脏巨噬细胞显著扩增。
- 这些巨噬细胞对凋亡中性粒细胞清除、炎症抑制和梗死心脏中修复性巨噬细胞表型诱导是必需的。
- 脾脏MMMs对MI后伤口愈合既必要又充分,并限制晚期病理性重构。
- 急性MI期间LXR-α激动剂诱导脾脏边缘区和MMMs扩增,减轻炎症并改善短期和长期心脏重构。
临床怎么用
- 靶向脾脏CD169+Tim4+MMMs或使用LXR-α激动剂扩增该群体,可能成为限制MI后不良重构和心力衰竭的治疗策略。
局限性
- 主要证据来自小鼠模型,人类数据仅为循环CD169+Tim4+细胞的观察性扩增,尚需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fidelity of wound healing after myocardial infarction (MI) is an important determinant of subsequent adverse cardiac remodeling and failure. Macrophages derived from infiltrating Ly6Chi (lymphocyte antigen 6 complex, locus C) blood monocytes are a key component of this healing response; however, the importance of other macrophage populations is unclear. METHODS: We used a variety of in vivo murine models and orthogonal approaches, including surgical MI, flow cytometry and single-cell RNA sequencing, lineage tracing and cell tracking, splenectomy, parabiosis, cell adoptive transfer, and functional characterization, to establish an essential role for splenic CD169+Tim4+ (cluster of differentiation 169+; T cell immunoglobulin- and mucin-domain-containing molecule 4) marginal metallophilic macrophages (MMMs) in post-MI wound healing in mice. Flow cytometry was used to measure circulating CD169+Tim4+ monocytes in humans with ST-segment-elevation MI and control participants with stable coronary artery disease undergoing elective percutaneous coronary intervention. RESULTS: Splenic CD169+Tim4+ MMMs circulate in blood as Ly6Clow monocytes expressing macrophage markers and help populate CD169+Tim4+CCR2-LYVE1low macrophages in the naive heart. After acute MI, splenic MMMs augment phagocytosis and CCR (C-C motif chemokine receptor) 3 and CCR4 expression, and robustly mobilize to the heart, resulting in marked expansion of cardiac CD169+Tim4+LYVE1low macrophages with an immunomodulatory and proresolving gene signature. These macrophages are obligatory for apoptotic neutrophil clearance, suppression of inflammation, and induction of a reparative macrophage phenotype in the infarcted heart. Splenic MMMs are both necessary and sufficient for post-MI wound healing, and limit late pathological remodeling. Liver X receptor-α agonist-induced expansion of the splenic marginal zone and MMMs during acute MI alleviates inflammation and improves short- and long-term cardiac remodeling. Humans with acute ST-segment-elevation MI also exhibit expansion of circulating CD169+Tim4+ cells, primarily within the intermediate (CD14+CD16+) monocyte population. CONCLUSIONS: Splenic CD169+Tim4+ MMMs are required for proresolving and reparative responses after MI and can be manipulated for therapeutic benefit to limit long-term heart failure.
引用
- Ismahil, Zhou, Rajasekar, et al. Splenic CD169+Tim4+ Marginal Metallophilic Macrophages Are Essential for Wound Healing After Myocardial Infarction. Circulation. 2025. PMID: 40289811. doi:10.1161/CIRCULATIONAHA.124.071772
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。